Apalutamide With or Without Stereotactic Body Radiation Therapy in Treating Participants With Castration-Resistant Prostate Cancer (PILLAR)
Study Details
Study Description
Brief Summary
This phase II trial studies the how well apalutamide with or without stereotactic body radiation therapy work in treating participants with castration-resistant prostate cancer. Testosterone can cause the growth of prostate cancer cells. Hormone therapy using apalutamide may fight prostate cancer by blocking the use of testosterone by the tumor cells. Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method can kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. It is not yet known whether giving apalutamide with or without stereotactic body radiation therapy works better in treating participants with castration-resistant cancer.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 2 |
Detailed Description
PRIMARY OBJECTIVE:
- To demonstrate whether the proportion of patients with an undetectable serum prostate specific antigen (PSA) at 6 months following cessation of apalutamide is higher with addition of stereotactic body radiation therapy (SBRT) to prostate specific membrane antigen (PSMA)-avid oligometastatic sites of disease compared to the group of patients receiving apalutamide monotherapy
SECONDARY OBJECTIVES:
-
To compare the time to PSA progression by Prostate Cancer Working Group (PCWG) criteria between treatment arms.
-
To evaluate the safety and tolerability of apalutamide in combination with SBRT.
EXPLORATORY OBJECTIVES:
-
To evaluate the genomic factors associated with the presence of oligometastatic disease via exome sequencing.
-
To evaluate the association between somatic and germline genomic alterations including but not limited to androgen receptor (AR) amplification and point mutations and alterations in deoxyribonucleic acid (DNA) damage response pathway with outcomes on protocol therapy.
-
To characterize the metastatic pattern at baseline and at progression in these patients and to determine whether features of the baseline PSMA-positron emission tomography (PET) scan are associated with treatment outcomes.
OUTLINE: Participants are randomized to 1 of 2 arms.
ARM I: Participants receive apalutamide orally (PO) once daily (QD) on days 1-28. Courses repeat every 28 days for up to 52 weeks in the absence of disease progression or unacceptable toxicity. Beginning 60 days after first dose of apalutamide, participants also undergo stereotactic body radiation therapy for 1-5 fractions.
ARM II: Participants receive apalutamide PO QD on days 1-28. Courses repeat every 28 days for up to 52 weeks in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, participants are followed at for 30 days.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Arm I (apalutamide, SBRT) Participants receive apalutamide PO QD on days 1-28. Courses repeat every 28 days for up to 52 weeks in the absence of disease progression or unacceptable toxicity. Beginning 60 days after first dose of apalutamide, participants also undergo stereotactic body radiation therapy for 1-5 fractions. |
Drug: Apalutamide
Given PO, 240 mg per day (4 x 60mg tablets)
Other Names:
Radiation: Stereotactic Body Radiation Therapy
Undergo SBRT
Other Names:
|
| Active Comparator: Arm II (SBRT) Participants receive apalutamide PO QD on days 1-28. Courses repeat every 28 days for up to 52 weeks in the absence of disease progression or unacceptable toxicity. |
Drug: Apalutamide
Given PO, 240 mg per day (4 x 60mg tablets)
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Proportion of patients with undetectable serum prostate-specific antigen (PSA) [Approximately 18 months from date of randomization]
The primary endpoint for the study is the proportion of patients with undetectable serum PSA (< 0.2 ng/mL) at 6 months following completion of apalutamide therapy (18 months from date of randomization). Patients who discontinue apalutamide prior to completion of 12 months of therapy for reasons other than disease progression by Prostate Cancer Clinical Trials Working Group (PCWG) criteria, as well as patients who withdraw or are lost to follow up, will be considered unevaluable for this analysis. Patients who discontinue treatment for radiographic or clinical progression, even if occurring prior to receipt of SBRT in the experimental arm), would be evaluable for analysis of the primary endpoint.
Secondary Outcome Measures
- Median Time to PSA Progression [Up to 36 months]
Time to a diagnosis of PSA progression defined by the Prostate Cancer Working Group (PCWG) criteria will be estimated using Kaplan-Meier methods for each treatment arm. Cox proportional-hazard models, will be used to estimate the hazard ratio and 95% confidence interval (CI).
- Frequency of treatment-related adverse events (AEs) [Up to 36 months]
For each treatment arm, adverse event incidence rates will be summarized with frequency and percentage, with all patients treated in that treatment arm as the denominator, unless otherwise specified. In addition, AE incidence rates will also be summarized by severity and relationship to study drug. Treatment-related AEs are those judged by the Investigator to be at least possibly related to the study treatment. Adverse events with missing severity or relationship to study drug will be classified as severe and treatment-related, respectively.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Histologically or cytologically confirmed adenocarcinoma of the prostate
-
Progressive, castration-resistant prostate cancer demonstrated during continuous antiandrogen therapy (ADT), defined as 3 PSA rises at least 1 week apart, with a minimum PSA > .05 ng/mL obtained during screening.
-
At least one but no more than 5 discrete PSMA-avid radiation fields on baseline PSMA-PET scan; all PSMA-avid lesions in radiation fields must be amenable to SBRT in judgment of treating radiation oncologist; there are no restrictions on site of lesion/radiation fields (e.g. bone, lymph node, prostate, visceral). Equivocal lesions/radiation fields on PSMA PET scan that are not definitive for metastasis will not count towards the limit of 5 radiation fields and will not undergo SBRT
-
Surgically or medically castrated, with testosterone levels of < 50 ng/dL during screening; if the patient is medically castrated, continuous dosing with luteinizing hormone-releasing hormone (LHRH) analogue must have been initiated at least 4 weeks prior to randomization and must be continued throughout the study to maintain castrate levels of testosterone including post-treatment follow up period
-
No prior systemic treatment initiated for the treatment of castration resistant prostate cancer, including abiraterone acetate, enzalutamide, apalutamide, darolutamide, other novel AR or CYP17 antagonist, or docetaxel.
-
Patients receiving bone loss prevention treatment with bone-modifying agents (e.g. denosumab, zoledronic acid) must be on stable doses for at least 4 weeks prior to randomization
-
Patients who received a first generation anti-androgen (e.g., bicalutamide, flutamide, nilutamide) as most recent treatment must have at least a 6-week washout prior to randomization and must show continuing disease (PSA) progression (an increase in PSA) after washout
-
At least 4 weeks or 5 half-lives, whichever is shorter, must have elapsed from the use of any anti-cancer therapy, other than Luteinizing hormone-releasing hormone (LHRH) analog or first generation antiandrogen, prior to randomization
-
At least 4 weeks must have elapsed from major surgery or radiation therapy prior to randomization
-
Age > 18 years
-
Eastern Cooperative Oncology Group (ECOG) performance status grade 0 or 1
-
Resolution of all acute toxic effects of prior therapy or surgical procedure to grade 1 or baseline prior to randomization
-
Serum aspartate transaminase (AST) ((serum glutamic oxaloacetic transaminase (SGOT])) and serum alanine transaminase (ALT) (( serum glutamic pyruvic transaminase (SGPT)) ≤ 2.5 x upper limit of normal (ULN)
-
Total serum bilirubin ≤ 1.5 x ULN; in subjects with known or suspected Gilbert's syndrome, if total bilirubin is > 1.5 x ULN, direct bilirubin is ≤ 1.5 x ULN
-
Glomerular filtration rate ≥ 45 ml/min based on Cockcroft-Gault equation
-
Absolute neutrophil count (ANC) ≥ 1500/microliter
-
Platelets ≥ 75,000/microliter without transfusion and/or growth factors in the 3 months prior to randomization
-
Hemoglobin ≥ 9.0 g/dL without transfusion and/or growth factors in the 3 months prior to randomization
-
Serum albumin ≥ 3.0 g/dL
-
Signed and dated informed consent document indicating that the patient has been informed of all pertinent aspects of the trial prior to randomization
-
Willingness and ability to comply with scheduled visits, treatment plans, laboratory and radiographic assessments, and other study procedures, including ability to swallow study drug tablets and long-term follow-up
-
Agrees to use a condom (even men with vasectomies) and another effective method of birth control if he is having sex with a woman of childbearing potential or agrees to use a condom if he is having sex with a woman who is pregnant while on study drug and for 3 months following the last dose of study drug; must also agree not to donate sperm during the study and for 3 months after receiving the last dose of study drug
Exclusion Criteria:
-
Presence of visceral lesions (e.g. lung, liver) detectable on baseline imaging or bone lesions requiring focal radiation treatment at the time of study entry
-
History of seizure or condition that may pre-dispose to seizure (e.g., prior stroke within 1 year prior to randomization, brain arteriovenous malformation, Schwannoma, meningioma, or other benign central nervous system (CNS) or meningeal disease which may require treatment with surgery or radiation therapy
-
Concurrent therapy with any of the following (all must have been discontinued or substituted for at least 1 week prior to randomization, except for medications known to lower seizure threshold which must be discontinued or substituted at least 4 weeks prior to randomization)
-
Medications known to lower the seizure threshold
-
Herbal (e.g., saw palmetto) and non-herbal (e.g., pomegranate) products that may decrease PSA levels
-
Systemic (oral/intravenous (IV)/intramuscular (IM)) corticosteroids; patients on chronic stable dose of steroids at an equivalent dose of prednisone ≤ 10 mg daily may be permitted to enroll at the discretion of principal investigator
-
Any other experimental treatment on another clinical trial
-
Any of the following within 6 months prior to randomization: Severe/unstable angina, myocardial infarction, symptomatic congestive heart failure, arterial or venous thromboembolic events (e.g., pulmonary embolism, cerebrovascular accident including transient ischemic attacks), or clinically significant ventricular arrhythmias
-
Uncontrolled hypertension at study entry; patients with a history of uncontrolled hypertension are allowed provided blood pressure is controlled by antihypertensive treatment
-
Gastrointestinal disorder affecting absorption
-
Secondary malignancy requiring active treatment except for non-melanoma skin cancer and superficial bladder cancer
-
Any medical condition that would be a contra-indication to radiation therapy, such as inflammatory bowel disease
-
Spinal cord compression or impending spinal cord compression
-
Any other condition that, in the opinion of the Investigator, would impair the patient's ability to comply with study procedures
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | University of California, San Francisco | San Francisco | California | United States | 94115 |
Sponsors and Collaborators
- University of California, San Francisco
- Janssen Pharmaceuticals
Investigators
- Principal Investigator: Rahul Aggarwal, MD, University of California, San Francisco
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 175519
- NCI-2018-00572